Alimera Sciences (Alimera Sciences) Asset Turnover

: 0.17 (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Alimera Sciences's Revenue for the three months ended in Dec. 2023 was $26.31 Mil. Alimera Sciences's Total Assets for the quarter that ended in Dec. 2023 was $153.86 Mil. Therefore, Alimera Sciences's Asset Turnover for the quarter that ended in Dec. 2023 was 0.17.

Asset Turnover is linked to ROE % through Du Pont Formula. Alimera Sciences's annualized ROE % for the quarter that ended in Dec. 2023 was -31.84%. It is also linked to ROA % through Du Pont Formula. Alimera Sciences's annualized ROA % for the quarter that ended in Dec. 2023 was -9.83%.

Alimera Sciences Asset Turnover Historical Data

The historical data trend for Alimera Sciences's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alimera Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Asset Turnover

1.03

1.01

1.08

1.07

0.82

Alimera Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Asset Turnover																0.33	0.30	0.17	0.15	0.17

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Alimera Sciences's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alimera Sciences Asset Turnover Distribution

For the Drug Manufacturers industry and Healthcare sector, Alimera Sciences's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Alimera Sciences's Asset Turnover falls into.

Alimera Sciences Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Alimera Sciences's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Asset Turnover
=	Revenue	/	Average Total Assets
=	Revenue (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
=	80.754	/	( (42.602	+	153.524)	/ 2 )
=	80.754	/	98.063
=	0.82

Alimera Sciences's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

	Asset Turnover
=	Revenue	/	Average Total Assets
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	26.306	/	( (154.192	+	153.524)	/ 2 )
=	26.306	/	153.858
=	0.17

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Alimera Sciences (NAS:ALIM) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Alimera Sciences's annulized ROE % for the quarter that ended in Dec. 2023 is

	ROE %^**		(Q: Dec. 2023 )
=	Net Income	/	Total Stockholders Equity
=	-15.124	/	47.505
=	(Net Income / Revenue)	*	(Revenue / Total Assets)	*	(Total Assets / Total Stockholders Equity)
=	(-15.124 / 105.224)	*	(105.224 / 153.858)	*	(153.858/ 47.505)
=	Net Margin %	*	Asset Turnover	*	Equity Multiplier
=	-14.37 %	*	0.6839	*	3.2388
=	ROA %	*	Equity Multiplier
=	-9.83 %	*	3.2388
=	-31.84 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

^** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Alimera Sciences's annulized ROA % for the quarter that ended in Dec. 2023 is

	ROA %		(Q: Dec. 2023 )
=	Net Income	/	Total Assets
=	-15.124	/	153.858
=	(Net Income / Revenue)	*	(Revenue / Total Assets)
=	(-15.124 / 105.224)	*	(105.224 / 153.858)
=	Net Margin %	*	Asset Turnover
=	-14.37 %	*	0.6839
=	-9.83 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.

Alimera Sciences Asset Turnover Related Terms

Thank you for viewing the detailed overview of Alimera Sciences's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Alimera Sciences (Alimera Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (NAS:ALIM) » Definitions » Asset Turnover

Comparable Companies

Traded in Other Exchanges

ASZ1:Germany

Address

6310 Town Square, Suite 400, Alpharetta, GA, USA, 30005

Website

https://www.alimerasciences.com

Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.

Executives

Margaret Pax	director	6310 TOWN SQUARE, SUITE 400, ALPHARETTA GA 30005
John Snisarenko	director	C/O ALIMERA SCIENCES, INC., 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Pizzo Peter J. Iii	director	6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Erin Parsons	director	97 WILLISTON RD, BROOKLINE MA 02445
Caligan Partners Lp	10 percent owner	515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Ross D Demont	director	51 PICKWICK ROAD, NEWTON MA 02465
C. Daniel Myers	other: Chairman Emeritus	6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
David Edward Johnson	10 percent owner	590 MADISON AVENUE, NEW YORK NY 10022
Velan Capital Master Fund Lp	10 percent owner	1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Management Llc	10 percent owner	1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Holdings Llc	10 percent owner	1055B POWERS PLACE, ALPHARETTA GA 30009
Adam Morgan	director	1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Investment Management Lp	10 percent owner	1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Spv I Llc	10 percent owner	1055B POWERS PLACE, ALPHARETTA GA 30009
Balaji Venkataraman	10 percent owner	FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076